Aribio Invited to Participate in JP Morgan Healthcare Conference... "Focusing on Partnering"

Aribio, which is in the process of merging with Solux, announced on the 6th that it has been invited to participate in the 'JPMorgan Healthcare Conference (JPMHC)' held in California, USA, from the 13th to the 16th of this month (local time).

Now in its 43rd year, JPMHC is the world's largest pharmaceutical and biotechnology event. More than 8,000 attendees from a total of 600 companies in the pharmaceutical, biotechnology, healthcare, and investment sectors are expected to participate.

At Aribio, Fred Kim, head of the US branch, and Tanya Xi, director of development strategy, will attend. They plan to hold meetings with multinational pharmaceutical companies and investment firms regarding key pipelines, including AR1001, an oral Alzheimer's disease treatment currently in global Phase 3 clinical trials. Meetings have been confirmed with numerous big pharma and global mid-sized pharmaceutical companies, and licensing and partnering negotiations will be actively pursued with companies that have continued discussions through last year's BioUSA and BioEurope. Additionally, discussions are planned with global investment institutions interested in new drug development.

The global Phase 3 clinical project for AR1001, called ‘Polaris-AD,’ is currently conducting final approval clinical trials targeting 1,150 early Alzheimer's disease patients across 13 countries, including the United States Food and Drug Administration (FDA), South Korea, the United Kingdom and European Union (EU), and China. Despite the addition of patient recruitment countries beyond the original plan, patient enrollment and dosing are proceeding smoothly, showing positive trends overall in safety and medication adherence.

Fred Kim, head of the branch, said, “Recently, we held a clinical investigator meeting in Beijing with professors and researchers from major university hospitals in China to accelerate patient recruitment for Polaris-AD,” adding, “Compared to the Phase 3 clinical trials of big pharma drugs such as lecanemab and donanemab, which received FDA approval for early Alzheimer's disease, our trial is progressing smoothly without any unusual trends.”

Aribio’s global Phase 3 clinical trial for AR1001 is expected to conclude early next year. After the topline results are announced next year, new drug approval applications (NDA) will be submitted starting with the FDA and then to the countries conducting the Phase 3 trials.

This content was produced with the assistance of AI translation services.